Page 2 - Maha Ha Hussain News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SUO 2020: Results from the PROfound Study, A New Second Line Therapy for mCRPC
(UroToday.com) In the second Prostate Cancer session at this year’s Society of Urologic Oncology virtual annual meeting, Dr. Maha Hussain discussed the role of poly ADP ribose polymerase (PARP) inhibitors, particularly olaparib, in metastatic castration-resistant prostate cancer.
Dr. Hussain began by reviewing the rationale for targeting PARP-1 in advanced prostate cancer given its implicated role in many aspects of prostate cancer including its role in mediating DNA repair response to alkylating agents, in cellular survival in BRCA deficient cells, and in androgen-receptor mediated prostate cancer cellular proliferation. Further, the Stand Up To Cancer (SU2C) project analysis demonstrated that more than 20% of patients with mCRPC harbor DNA repair pathway aberrations including BRCA2, BRCA1, ATM and many others of which 8-10% are pathogenic germline findings. ....

United States , Foundationone Cdx , Christopher Jd Wallis , Maha Ha Hussain , Maha Hussain , Olaparib Lynparza , Society Of Urologic Oncology Annual Meeting , Society Of Urologic Oncology , Drug Administration , Northwestern University Feinberg School Of Medicine , Department Of Medicine , Division Of Hematology , Prostate Cancer , Urologic Oncology , Stand Up To Cancer , Versus Enzalutamide , Abiraterone Acetate , New England Journal , Homologous Recombination Gene Deficiency , Federal Drug Administration , Genevieve Teuton Professor , Northwestern University Feinberg School , Urologic Oncology Annual Meeting , ஒன்றுபட்டது மாநிலங்களில் , கிறிஸ்டோபர் ஜ்ட் வாலிஸ் , மஹா எச்ஏ ஹுசைன் ,